Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9.

Published byDarleen Porter Modified over 6 years ago

Similar presentations

Presentation on theme: "Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9."— Presentation transcript:

1 Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9 and a Decline in Serum-Soluble E-Cadherin  Karen L. Reckamp, MD, Brian K. Gardner, PhD, Robert A. Figlin, MD, David Elashoff, PhD, Kostyantyn Krysan, PhD, Mariam Dohadwala, PhD, Jenny Mao, MD, Sherven Sharma, PhD, Landon Inge, PhD, Ayyappan Rajasekaran, PhD, Steven M. Dubinett, MD  Journal of Thoracic Oncology  Volume 3, Issue 2, Pages (February 2008) DOI: /JTO.0b013e bef Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Soluble E-cadherin (sEC) decreases in patients treated with celecoxib and erlotinib who achieve partial response. sEC was evaluated by enzyme linked immunosorbent assay in patient serum at baseline and at week 8 of treatment. A, All patients at weeks 0, 4, and 8, *p = 0.021—decline in patients with PR compared with those with SD and PD. Individual patient values for (B) patients with PR; (C) patients with SD; and (D) patients with PD. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e bef) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 MMP-9 is lower at baseline and after 8 weeks in patients treated with celecoxib and erlotinib who achieve partial response. MMP-9 was evaluated by enzyme linked immunosorbent assay in patient serum at baseline and at week 8 of treatment. A, All patients at weeks 0 and 8, *p = 0.006—baseline values of patients with PR compared with those with SD and PD Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e bef) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 TIMP-1 is lower in patients treated with celecoxib and erlotinib who achieve partial response. TIMP-1 was evaluated by enzyme linked immunosorbent assay in patient serum at baseline and at week 8 of treatment. A, All patients at weeks 0 and 8, *p = 0.047—decreased levels in patients with PR compared with those with SD and PD. Individual patient values for (B) patients with PR; (C) patients with SD; and (D) patients with PD. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e bef) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 CCL15 decreases in patients treated with celecoxib and erlotinib who achieve partial response. CCL15 was evaluated by enzyme linked immunosorbent assay in patient serum at baseline and at week 8 of treatment. A, All patients at weeks 0, 4, and 8, *p = 0.016—decline in patients with PR compared with those with SD and PD at week 4, **p = 0.003—decline in patients with PR compared with those with SD and PD at week 8. Individual patient values for (B) patients with PR; (C) patients with SD; and (D) patients with PD. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e bef) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9."

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer  Peter M.

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer  Peter M.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation  Angela M. Davies, MD, Cheryl.

Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation  Angela M. Davies, MD, Cheryl.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy  Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy  Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance  Kostyantyn Krysan, PhD,

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance  Kostyantyn Krysan, PhD,
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.

Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.

Similar presentations

Ads by Google